• The company announced a strategic split between its MRD cancer-testing diagnostics business and its Immune Medicine drug-discovery arm to optimize its business structure.
  • Adaptive priced an upsized $300 million private convertible notes offering, a move that initially pressured shares due to dilution concerns but is now seeing a partial recovery as investors digest the long-term strategy.